1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof

1. A compound of formula I

wherein

X is NH;

R1 is (C 1 -C 6 )-alkyl;

R2, is OH;

R2′ is H;

R3, R3′, R4, R4′, R5, R5′, are, independently of one another, H, Cl, Br, I, OH, —(CH 2 )—OH, CF 3 , NO 2 , N 3 , CN, S(O) p —R6, O—S(O) p —R6, (C 1 -C 6 )-alkylene-S(O) p —R6, (C 1 -C 6 )-alkylene-O —S(O) p —R6, COOH, COO(C 1 -C 6 )alkyl, CONH 2 , CONH(C 1 -C 6 )alkyl, CON[(C 1 -C 6 )alkyl] 2 , (C 1 -C 6 )-alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )-alkynyl, O—(C 1 -C 6 )-alkyl, where one, more than one, or all hydrogen(s) in the alkyl radicals may be replaced by fluorine;

phenyl, —(CH 2 )-phenyl, —(CH 2 ) 2 -phenyl, O-phenyl, O—(CH 2 ) m -phenyl, —(CH 2 )—O—(CH 2 ) m -phenyl, where the phenyl ring may be substituted one to 3 times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N((C 1 -C 6 )-alkyl) 2 , SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl or CONH 2 ;

wherein at least one of the radicals R3, R3′, R4, R4′, R5, R5′ has the meaning of (C 1 -C 6 )-alkylene-O —S(O) p —R6 and another has the meaning of —O—(CH 2 ) m -phenyl, where the phenyl ring may be substituted one to 3 times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N((C 1 -C 6 )-alkyl) 2 , SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl or CONH 2 ;

R6 is H, OH, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl or N((C 1 -C 6 )-alkyl) 2 ;

n is 2, 3, 4, 5 or 6;

m is 1, 2, 3, 4, 5 or 6;

P is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein

X is NH;

R1 is (C 1 -C 6 )-alkyl;

R2, is OH;

R2′ is H;

R5′ is (C 1 -C 6 )-alkylene-O—S(O) 2 —R6;

R3, R3′, R4, R4′, R5 are, independently of one another, H, Cl, Br, I, OH, —(CH 2 )—OH, CF 3 , NO 2 , N 3 , CN, S(O) p —R6, O—S(O) p —R6, (C 1 -C 6 )-alkylene-S(O) p —R6, (C 1 -C 6 )-alkylene-O —S(O) p —R6, COOH, COO(C 1 -C 6 )alkyl, CONH 2 , CONH(C 1 -C 6 )alkyl, CON[(C 1 -C 6 )alkyl] 2 , (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, O—(C 1 -C 6 )-alkyl, where one, more than one, or all hydrogen(s) in the alkyl radicals may be replaced by fluorine;

phenyl, —(CH 2 )-phenyl, —(CH 2 ) n -phenyl, O-phenyl, O—(CH 2 ) m -phenyl, —(CH 2 )—O—(CH 2 ) m -phenyl, where the phenyl ring may be substituted one to 3 times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N((C 1 -C 6 )-alkyl) 2 , SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl or CONH 2 ;

wherein at least one of the radicals R3, R3′, R4, R4′, R5, R5′ has the meaning of —O—(CH 2 ) m -phenyl, where the phenyl ring may be substituted one to 3 times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N((C 1 -C 6 )-alkyl) 2 , SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl or CONH 2 ;

R6 is H, OH, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl or N((C 1 -C 6 )-alkyl) 2 ;

n is 2, 3, 4, 5 or 6;

m is 1, 2, 3, 4, 5 or 6;

or a pharmaceutically acceptable salt thereof.

3. A compound of the formula

or a pharmaceutically acceptable salt thereof.

4. A compound of the formula

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 3 or 4 , wherein the pharmaceutically acceptable salt is an ammonium salt.

6. The compound of claim 3 or 4 , wherein the pharmaceutically acceptable salt is an alkali metal or alkaline earth metal salt.

7. The compound of claim 3 or 4 , wherein the pharmaceutically acceptable salt is a potassium salt.

8. The compound of claim 3 or 4 , wherein the pharmaceutically acceptable salt is a zinc salt.

9. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of claim 1 .

10. The pharmaceutical composition of claim 9 which comprises at least one further active ingredient, wherein said at least one further active ingredient is a compound which normalizes lipid metabolism.

11. The pharmaceutical composition of claim 9 , which comprises at least one further active ingredient, wherein said at least one further active ingredient is selected from the group comprising one or more antidiabetics, hypoglycemic active ingredients, HMGCoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, PPAR delta agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, MTP inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP-citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, HM74A receptor agonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-glucosidase inhibitors, active ingredients which act on the ATP-dependent potassium channel of the beta cells, glycogen phosphorylase inhibitors, glucagon receptor antagonists, activators of glucokinase, inhibitors of gluconeogenesis, inhibitors of fructose-1,6-bisphosphatase, modulators of glucose transporter 4, inhibitors of glutamine-fructose-6-phosphate amidotransferase, inhibitors of dipeptidylpeptidase IV, inhibitors of 11-beta-hydroxysteroid dehydrogenase 1, inhibitors of protein tyrosine phosphatase 1B, modulators of the sodium-dependent glucose transporter 1 or 2, modulators of GPR40, inhibitors of hormone-sensitive lipase, inhibitors of acetyl-CoA carboxylase, inhibitors of phosphoenolpyruvate carboxykinase, inhibitors of glycogen synthase kinase-3 beta, inhibitors of protein kinase C beta, endothelin-A receptor antagonists, inhibitors of I kappaB kinase, modulators of the glucocorticoid receptor, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, β3 agonists, CB 1 receptor antagonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotoninergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, diphenylazetidinone derivatives, leptin agonists, DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR-β agonists or amphetamines.

12. A method of treating hyperlipidemia comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

13. A method of lowering the serum cholesterol level comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

14. A method of treating arteriosclerosis comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

15. A method of treating Syndrome X in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.